FDA Advisors Recommend Approval Of Topotecan for Ovarian Cancer
In Brief: Louise Strong Named President, AACR; Donald Coffey Is President-Elect
Cancer Drugs Initiatives To Shorten approval Times, Ensure Post-Marketing Studies, FDA Official Says
House Committee Asks Varmus About Impact of Clinical Center construction On NIH Programs
Centers May Become More specialized, Klausner Tells AACI
NIH, NCI Being Discussions With HCFA On Reimbursement
Trending Stories
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home









